The following links are provided solely as a resource for informational purposes only and are not intended to provide any medical advice, opinions or conclusions. 

MabThera (Rituxan, rituximab)   

Bendamustine and Rituximab - Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial 

 Sigbjørn  Berentsen et al  Google Search


Fludaribine and Rituximab
High response rate and durable remissions following fludarabine and  rituximab combination therapy for chronic cold agglutinin disease.
Sigbjørn  Berentsen et al Google Search 

Warm Heart Surgery for those with Cold Agglutinin Disease

Global Genes – Rare Disease Foundation Alliance:

NORD – National Organization for Rare Disorders in US:

CORD - Canadian Organization Rare Disorders:

The Leukemia & Lymphoma Society:

Bing Center for Waldenström’s Research/ Dana Farber/Harvard Cancer Center has some relevant information for Cold Agglutinin Disease:

Waldenström’s Macroglobulinemia – Research, Treatment, Support:

American Autoimmune Related Diseases:

Search for “Cold Agglutinin Disease” or Autoimmune Hemolytic Anemia

PubMed service of the U.S. National Library of Medicine and the National Institutes of Health

Merck Manual Home edition:

Medline Plus:

Blood Journal: American Society of Hematology Publication

Clinical trials database

Autoimmunity Research Foundation: 

National Heart Lung and Blood Institute:

American Society of Hematology:

Raynaud’s Phenomenon: search 

How blood works: 


Medic Alert:

2020 - Uncover the facts about cold agglutinin disease

2019 - Cold agglutinin disease: current challenges and future prospects S. Berentsen, Alexander Röth, Ulla Randen, Bernd Jilma, Geir E TjØnnfjord

2019 - Cold agglutinins: fending off the attack| Blood | American Society of Hematology Blood (2019) 133 (9): 885-886  Sigbjørn  Berentsen

2019 - Inhibition of complement C1s improves severe hemolytic anemia in cold
agglutinin disease: a first-in-human trial Blood (2019)133 (9):893-901.  Ulrich Jäger, Shirley D’Sa et al

2019 - Novel insights into the treat of complement-mediated hemolytic anemia Berentsen S, Hill A, Hill QA, Tvedt THA, Michael M

2018 - How I manage patients with cold agglutinin disease Br J Haematology/ Volume 181, Issue 3  Berentsen S

 2018 – Autoimmune hemolytic anemia American Society of Hematology Edu Program Anita Hill and Quentin A. Hill

2018 - Cold Agglutinin Disease: Medscape Salman Abdullah Ajubran, MD et al

2016 - ANX005, an Inhibitory Antibody Against C1q, Blocks Complement Activation triggered by Cold Agglutinins in Human Disease  Morie A Gertz Blood (2016) 128 (22):1265  

2015 - Safety, Tolerability and Activity of TNT009 in Healthy Volunteers and Patients With Complement Mediated Disorders (TNT009-01)

*2014 -TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins

*Early study of Sutimlimab acknowledging the 40 CADdy Chatter Patients who donated the blood plasma samples used for this study.

2014 -Treatment of autoimmune hemolytic anemias

2014 -Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma

2014 - Picture of Blood Human Anatomy by Matthew Hoffman, MD

Celebrate International Rare Disease Day – Annually February 28th or 29th
Rare Disease Day was established in 2008 to raise awareness about rare diseases which impact millions of people worldwide. It also highlights the importance of research to develop diagnostics and treatments to address unmet medical needs.  It is supported by the National Institutes of Health (NIH) Office of Rare Diseases Research, the NIH Clinical Center, the NIH Institutes and Centers, the Health Resources and Services Administration (HRSA), the Food & Drug Administration’s Office of Orphan Product Development (OOPD), the National Organization for Rare Disorders (NORD), and the Genetic Alliance.